Recent trials investigating the efficacy of first-line immune checkpoint inhibition in recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) showed that PD-L1 expression is associated with an increased ORR in patients with CPS ≥1 [80,81]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.